Macquarie Group’s ANI Pharmaceuticals ANIP Stock Holding History

Macquarie Group’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Buy	+164	New	+$13.2K	﹤0.01%	906
2025 Q4	–	Sell	-291,129	Closed	-$26.7M	–	885
2025 Q3	$26.7M	Sell	291,129 -132,588	-31%	-$10.8M	0.03%	580
2025 Q2	$27.6M	Sell	423,717 -25,118	-6%	-$1.64M	0.03%	575
2025 Q1	$30.1M	Sell	448,835 -113,768	-20%	-$6.8M	0.04%	545
2024 Q4	$31.1M	Buy	562,603 +70,956	+14%	+$4.07M	0.04%	543
2024 Q3	$29.3M	Buy	491,647 +103,570	+27%	+$6.32M	0.03%	588
2024 Q2	$24.7M	Buy	388,077 +174,178	+81%	+$11.3M	0.03%	609
2024 Q1	$14.8M	Sell	213,899 -16,163	-7%	-$976K	0.02%	741
2023 Q4	$12.7M	Buy	+230,062	New	+$12.7M	0.01%	775
2018 Q4	–	Sell	-200	Closed	-$11K	–	2244
2018 Q3	$11K	Buy	+200	New	+$12.2K	﹤0.01%	1980

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's ANIP Position: Q2 2026 in Review

Macquarie Group opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 164 shares worth $13.6K. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings. This is a return to the name: Macquarie Group previously reported a position in ANIP as recently as Q3 2025.

Macquarie Group first reported a position in ANIP in Q3 2018 and has held it in 10 quarters since. The position peaked at $31.1M in Q4 2024. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Macquarie Group held 164 shares of ANI Pharmaceuticals worth $13.6K as of Q2 2026.
ANI Pharmaceuticals was a new Macquarie Group position in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #906 holding.
Macquarie Group first reported a position in ANI Pharmaceuticals in Q3 2018 and has held it in 10 quarters since.
Macquarie Group's ANI Pharmaceuticals position peaked at $31.1M in Q4 2024.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.